Neuropsychopharmacology

Psilocybin therapy may enhance emotional well-being in Parkinson's patients

May 2, 2025

Study details: This open-label pilot trial (NCT04932434) investigated the feasibility of psilocybin therapy for mood dysfunction in Parkinson's disease (PD). Twelve participants with mild to moderate PD and comorbid depression and/or anxiety received two doses of psilocybin (10 mg and 25 mg) combined with psychotherapy.

Results: The study reported no serious adverse events or exacerbation of psychosis. Common adverse events included anxiety, nausea, and increased BP. Improvements were observed in non-motor and motor symptoms, as well as cognitive performance. Depression and anxiety scores significantly improved post-treatment and were sustained for up to three months.

Clinical impact: This pilot trial provides preliminary evidence that psilocybin therapy may be safe and beneficial for mood dysfunction in PD, warranting further investigation in larger, controlled studies.

^Source:

Bradley ER, et al. (2025, April 9). Neuropsychopharmacology. Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. https://pubmed.ncbi.nlm.nih.gov/40205013/